PXT864: PLEODIAL-II extension study data

Data from 37 patients with mild AD in the open-label PLEODIAL-II extension of the single-blind, French Phase II PLEODIAL-I trial showed that twice-daily low-, mid- and high-dose oral PXT864 increased ...